Dr. Nicholas Alfred Blondin, MD

Dr. Blondin practices at Yale Medicine in New Haven, Connecticut.

Dr. Blondin's NPI, 1699940551, was assigned on April 22, 2008. Dr. Blondin graduated from Uconn School Of Medicine in 2008. Dr. Blondin holds Connecticut license 050680.

Dr. Blondin's primary practice is Yale Medicine, at 50 Division St, New Haven, CT 06511 in South Central Ct County. The practice phone is (203) 785-2140.

Dr. Blondin's primary practice is Yale Medicine in New Haven, Connecticut. Dr. Blondin is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Blondin to 3 more hospitals, 3 group practices and clinics, 2 medical groups and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Blondin practices, 8 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Blondin's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Blondin is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Blondin is licensed in Connecticut.

Dmand AI lists acute mini-stroke (TIA), cerebrovascular disease, epilepsy, hereditary polyneuropathy, lower back pain, multiple sclerosis, neuropathy and non-alzheimer's dementia (chronic) among the conditions Dr. Blondin treats.

CMS data shows 491 Medicare services from Dr. Blondin across 4 procedure codes in 2024, for 184 Medicare patients. Medicare paid $38,181 for them.

CMS counts 184 Medicare patients who saw Dr. Blondin in 2024. The largest group is 65 to 74, with 74 patients. 73% of them have high cholesterol, and 66% have high blood pressure. 24% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Blondin's median patient age at 67, with 56% women.

In 2024, Dr. Blondin wrote 1,020 Medicare Part D claims for 175 patients. 88% of them were for generic drugs. CMS names the drug for 689 of them, across 28 drugs with 11 or more claims each, at $864,868 in total drug cost. In 2023, CMS named 643 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Blondin for performance year 2024, reported as part of a group. Dr. Blondin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Blondin as offering telehealth.

Dmand AI links 26 papers to Dr. Blondin, published from 2010 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Brain Neoplasms, Glioma and Neoplasm Grading. Dr. Blondin has published most often in Arch Neurol. Dr. Blondin's most frequent co-authors are Neelan Joseph Marianayagam, MD, PhD, Zachary Andrew Corbin, MD, MHS and Elena I. Fomchenko, MD, PhD.

Dmand AI links Dr. Blondin to 10 clinical trials, 6 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Glioblastoma, Gliosarcoma and Alzheimer Disease. NRG Oncology sponsors the most, 3.

CMS Open Payments shows 664 general payments to Dr. Blondin from 44 drug and device companies from 2016 to 2024. Honoraria make up the largest share, 50% of the total. Novocure Inc. paid the most, $160,686. It also lists 2 research payments totaling $1,250 in 2017.

Dmand AI lists 19 awards for Dr. Blondin, most recently Humanitarian Award in 2018.

Dr. Blondin graduated from Uconn School Of Medicine in 2008. Dr. Blondin is a member of AAN, ASCO and Society for Neuro-Oncology.

Dr. Blondin is in network with 16 carriers, including Elevance, United Healthcare and Cigna. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.